Shareholder Update October 2017

Oct 18, 2017

In this issue:

>> DEP^® docetaxel achieves positive phase 1 results and commences phase 2

>> AZ presents first DEP^® candidate AZD0466 – a Bcl2/xL inhibitor

>> Successful VivaGel^® BV phase 3 results

>> Update on other internal DEP^® candidates

>> Grant awarded to Starpharma-Monash

>> Starpharma and Peter Mac Cancer Centre awarded grant

>> FY17 Financial results; >$60M cash at 30 June

>> Annual Report and Annual General Meeting

>> Starpharma News & Events

Download: Shareholder Update October 2017 (pdf file, 1.3mb)